ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease Paris and Parsippany, NJ, February 22, 2025. Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 monoclonal antibody targeting TL1A, in…
Posted: 2025-02-22 07:30:00
